Identification of HLA class I-binding peptides derived from unique cancer-associated proteins by mass spectrometric analysis

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 1853-1859

  Kamata, Yuko ^a   Kuhara, Akiko ^a   Iwamoto, Takeo ^a   Hayashi, Kazumi ^a   Koido, Shigeo ^a   Kimura, Takahiro ^a   Egawa, Shin ^a   Homma, Sadamu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antigenic peptide; Cancer associated antigen; HLA class I; Mass spectrometric analysis; Prostate cancer

Indexed keywords

MEMBRANE PROTEIN; MESSENGER RNA;

ANTIGEN BINDING; ARTICLE; CEREBELLUM; HLA SYSTEM; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MELANOMA; OVARY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TESTIS;

ANTIGENIC PEPTIDE; CANCER ASSOCIATED ANTIGEN; HLA CLASS-I; MASS SPECTROMETRIC ANALYSIS; PROSTATE CANCER;

CHROMATOGRAPHY, LIQUID; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84878195772     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Mlecnik B, Bindea G, Pagès F and Galon J: Tumor immunosurveillance in human cancers. Cancer Metastasis Rev 30: 5-12, 2011.
2. Bindea G, Mlecnik B, Fridman WH, Pagès F and Galon J: Natural immunity to cancer in humans. Curr Opin Immunol 22: 215-222, 2010.
3. Hamaï A, Benlalam H, Meslin F, Hasmim M, Carré T, Akalay I, Janji B, Berchem G, Noman MZ and Chouaib S: Immune surveillance of human cancer: If the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens 75: 1-8, 2010.
4. Draghiciu O, Nijman HW and Daemen T: From tumor immunosuppression to eradication: Targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol 2011: 439053, 2011.
5. Stewart TJ and Smyth MJ: Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev 30: 125-140, 2011.
6. Bhutia SK, Mallick SK and Maiti TK: Tumour escape mechanisms and their therapeutic implications in combination tumour therapy. Cell Biol Int 34: 553-563, 2010.
7. Palena C and Schlom J: Vaccines against human carcinomas: Strategies to improve antitumor immune responses. J Biomed Biotechnol 2010: 380697, 2010.
8. Mocellin S, Pilati P and Nitti D: Peptide-based anticancer vaccines: Recent advances and future perspectives. Curr Med Chem 16: 4779-4796, 2009.
9. O'Meara MM and Disis ML: Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: Emerging applications toward proof of concept. OMICS 15: 579-588, 2011.
10. Adamczyk-Poplawska M, Markowicz S and Jagusztyn-Krynicka EK: Proteomics for development of vaccine. J Proteomics 74: 2596-2616, 2011.
11. Shetty V, Sinnathamby G, Nickens Z, Shah P, Hafner J, Mariello L, Kamal S, Vlahović G, Lyerly HK, Morse MA and Philip R: MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T-cell response. J Proteomics 74: 728-743, 2011.
12. Seliger B, Dressler SP, Massa C, Recktenwald CV, Altenberend F, Bukur J, Marincola FM, Wang E, Stevanovic S and Lichtenfels R: Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells. Proteomics 11: 2528-2541, 2011.
13. Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, Osada T, Hafner J, Philip M, Clay TM, Lyerly HK and Philip R: MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res 17: 3408-3419, 2011.
14. Matharoo-Ball B, Ball G and Rees R: Clinical proteomics: Discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches - a prostate cancer perspective. Vaccine 25(Suppl 2): B110-121, 2007. (Pubitemid 47488553)
15. Apetoh L, Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Piacentini M, Kroemer G and Zitvogel L: Immunogenic chemotherapy: Discovery of a critical protein through proteomic analyses of tumor cells. Cancer Genomics Proteomics 4: 65-70, 2007. (Pubitemid 46632027)
16. Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, Miller CL, Myers HE, McDaniel M, Karns LR, Kiessling R, Parmiani G and Flyer DC: Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T-cells. Int Immunol 15: 751-763, 2003. (Pubitemid 36675806)
17. Homma S, Koido S, Sagawa Y, Suzuki H, Komita H, Nagasaki E, Takahara A, Horiguchi-Yamada J, Tajiri H, Zeldin DC and Obata T: Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti-tumour immunity. Clin Exp Immunol 156: 344-352, 2009.
18. Honma I, Torigoe T, Hirohashi Y, Kitamura H, Sato E, Masumori N, Tamura Y, Tsukamoto T and Sato N: Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer. J Transl Med 7: 103, 2009.
19. Herr W, Ranieri E, Gambotto A, Kierstead LS, Amoscato AA, Gesualdo L and Storkus WJ: Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc Natl Acad Sci USA 96: 12033-12038, 1999. (Pubitemid 29502853)
20. Ray ME, Su YA, Meltzer PS and Trent JM: Isolation and characterization of genes associated with chromosome-6 mediated tumor suppression in human malignant melanoma. Oncogene 12: 2527-2533, 1996. (Pubitemid 26237781)
21. Ray ME, Wistow G, Su YA, Meltzer PS and Trent JM: AIM1, a novel non-lens member of the betagamma-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma. Proc Natl Acad Sci USA 94: 3229-3234, 1997. (Pubitemid 27157293)
22. Vainio P, Mpindi JP, Kohonen P, Fey V, Mirtti T, Alanen KA, Perälä M, Kallioniemi O and Iljin K: High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. PLoS One 7: e39801, 2012.
23. Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, Marusina K, Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, Casavant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak SA, McEwan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madan A, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones SJ and Marra MA: Mammalian Gene Collection Program Team. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA 99: 16899-16903, 2002. (Pubitemid 36034070)
24. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol Rev 188: 22-32, 2002. (Pubitemid 35398862)
25. Lim SH, Zhang Y and Zhang J: Cancer-testis antigens: The current status on antigen regulation and potential clinical use. Am J Blood Res 2: 29-35, 2012.
26. Caballero OL and Chen YT: Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci 100: 2014-2021, 2009.
27. Cheng YH, Wong EW and Cheng CY: Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. Spermatogenesis. 1: 209-220, 2011.
28. Meek DW and Marcar L: MAGE-A antigens as targets in tumour therapy. Cancer Lett 324: 126-132, 2012.
29. Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, Knuth A, Chen YT and Old LJ: NY-ESO-1: Review of an immunogenic tumor antigen. Adv Cancer Res 95: 1-30, 2006. (Pubitemid 44088423)